The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure

Canadian Journal of Cardiology

Volumn 19, Issue 4, 2003, Pages 347-356

  Liu, Peter ^a   Arnold, J Malcolm O ^b   Belenkie, Israel ^c   Demers, Catherine ^d   Dorian, Paul ^a   Gianetti, Nadia ^e   Haddad, Haissam ^f   Howlett, Jonathan ^g   Ignazewski, Andrew ^h   Jong, Philip ^a   McKelvie, Robert ^d   Moe, Gordon ^a   Parker, John D ^a   Rao, Vivek ^a   Rouleau, Jean L ^a   Teo, Koon ^d   Tsuyuki, Ross ⁱ   White, Michael ^j   Huckel, Victor ^h   Issac, Debra ^c   Johnstone, David ^g   LeBlanc, Marie Helene ^k   Lee, Hui ^m   Newton, Gary ^a   Niznick, Joel ^m   Ross, Heater ^a   Roth, Sherryn ^m   Roy, Dennis ^j   Smith, Stuart ^m   Sussex, Bruce ^l   Yusuf, Salim ^d   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j UNIVERSITÉ DE MONTRÉAL   (Canada)

^k UNIVERSITÉ LAVAL   (Canada)

^l MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CREATINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HORMONE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; IRBESARTAN; LISINOPRIL; LOSARTAN; NESIRITIDE; NITRATE; PLACEBO; RAMIPRIL; SPIRONOLACTONE; VALSARTAN; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; ARTICLE; ARTIFICIAL HEART PACEMAKER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; CREATININE BLOOD LEVEL; DEFIBRILLATOR; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG USE; DYSPNEA; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE FACILITIES AND SERVICES; HEALTH PROGRAM; HEART DILATATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART SURGERY; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; LUNG DISEASE; MAXIMUM TOLERATED DOSE; MEDICAL ASSESSMENT; MEDICAL PRACTICE; MEDICAL SOCIETY; META ANALYSIS; MORBIDITY; MORTALITY; PATIENT EDUCATION; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; CANADA; CARDIOLOGY; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; SOCIETIES, MEDICAL;

EID: 0037615208     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
2. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial: The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
3. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
4. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, Val-HeFT Investigators. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-21.
5. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM): Rationale and design. J Card Fail 1999;5:276-82.
6. Jong P, Demers C, McKelvie R, Liu P. Angiotensin receptor blockers in heart failure: Meta-analysis of randomized controlled trial. J Am Coll Cardiol 2002;39;463-70.
7. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.
8. Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): Rationale and design. Am Heart J 2000;140;727-50.
9. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 2000;342:1937-45.
10. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-90.
11. Moss AJ, Zareba W, Hall WJ, et al, The Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
12. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002;106:2145-61.
13. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: The Cardiomyopathy Trial (CAT). Circulation 2002;105:1453-8.
14. Connolly SJ, Krahn A, Klein G. Long term management of the survivor of ventricular fibrillation or sutained ventricular tachycardia. Can J Cardiol 2000;16(Suppl C):2C-20C.
15. Cazeau S, Leclercq C, Lavergne T, et al, Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-80.
16. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: Results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111-8.
17. Abraham WT, Fisher WG, Smith AL, et al, MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53.
18. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail 2000;6:276-85.
19. Moe GW. Natriuretic peptide in heart failure. In: Braunwald E, Fauci AS, Isselbacher KJ, et al, eds. Harrison's Online. New York: McGraw-Hill; 2002.
20. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994;343:440-4.
21. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
22. Maisel AS, Krishnaswamy P, Nowak RM, et al, Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
23. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-9.
24. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J AM Coll Cardiol 2001;37:386-91.
25. Lee SC, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002;8:149-54.
26. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
27. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham heart study. JAMA 2000;288:1252-9.
28. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
29. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002;287:1531-40.
30. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nisiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
31. Lubien EDA, Kirshnaswamy P, Clopton P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002;105:595-601.
32. Kasper EK, Gerstenblith G, Hefter G, et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 2002;39:471-80.
33. Stewart S, Horowitz JD. Home-based intervention in congestive heart failure: Long-term implications on readmission and survival. Circulation 2002;105:2861-6.
34. Naylor MD, Brooten D, Campbell R, et al. Comprehensive discharge planning and home follow-up of hospitalized elders: A randomized clinical trial. JAMA 1999;281:613-20.
35. Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol 2002;39:83-9.
36. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
37. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: A randomised controlled study. Lancet 1999;354:1077-83.
38. Blue L, Lang E, McMurray JJ, et al. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ 2001;323:715-8.
39. Cline CM, Israelsson BY, Willenheimer RB, Broms K, Erhardt LR. Cost effective management programme for heart failure reduces hospitalisation. Heart 1998;80:442-6.
40. McDonald K, Ledwidge M, Cahill J, et al. Heart failure management: Multidisciplinary care has intrinsic benefit above the optimization of medical care. J Card Fail 2002;8:142-8.
41. Riegel B, Carlson B, Glaser D, Hoagland P. Which patients with heart failure respond best to multidisciplinary disease management? J Card Fail 2000;6:290-9.
42. Rose EA, Gelijns AC, Moskowitz AJ, et al, Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001;345:1435-43.